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Edited by Gianni CesareniAbstract The sequence of Bcl-2 homology domains, BH1 and
BH2, is known to be conserved among anti- and pro-apoptotic
members of Bcl-2 family proteins. But structural conservation
of these domains with respect to functionally active residues
playing role in heterodimerization-mediated regulation of apop-
tosis has never been elucidated. Here, we have suggested the for-
mation of an active site by structurally conserved residues in
BH1 (glycine, arginine) and BH2 (tryptophan) domains of Bcl-
2 family members, which also accounts for the functional eﬀect
of known mutations in BH1 (G145A, G145E) and BH2
(W188A) domains of Bcl-2.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Heterodimerization; Docking; Mutation1. Introduction
Bcl-2 family members play an important role in embryogen-
esis, tissue remodeling and immune response through their
action as either inhibitors (anti-apoptotic) or promoters (pro-
apoptotic) of apoptosis. Bcl-2 family members are classiﬁed
as anti-apoptotic or pro-apoptotic on the basis of possessingAbbreviations: BH, Bcl-2 Homology; G, Glycine; A, Alanine; K,
Lysine; E, Glutamic acid; R, Arginine; W, Tryptophan; 1MAZ, E. coli
Bcl-XL (GI 2098338); 1BXL, E. coli Bcl-XL/Bak complex (GI 26246-
21); 1PQ0, Mouse Bcl-XL (GI 37927566); 1PQ1, Mouse Bcl-XL/Bim
complex (GI 37927568); 1WSX, Mouse Mcl-1 (GI 56966992); 1AF3,
Rat Bcl-XL (GI 2392082); 1G5M, Human Bcl-2 Isoform 1 (GI 1378-
6963); 1GJH, Human Bcl-2 Isoform 2 (GI 14719780); 1LXL, Human
Bcl-XL (GI 2098333); 1R2D, Human Bcl-XL (GI 42543462); 1G5J,
Human Bcl-XL/Bad complex (GI 13096159); 1MK3, Human Bcl-W
(GI 31615587); 1F16, Human Bax-alpha (GI 11513492); 1Q59A, EB2
virus BHRF-1 protein (GI 37927821); 1K3K, Kaposis sarcoma virus 2
(GI 20663999); 1TY4, C. elegans CED-9/EGL-1 complex (GI 55670-
071)
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doi:10.1016/j.febslet.2005.05.015Bcl-2 homology domains (BH) i.e., BH1, BH2, BH3 and
BH4. Several anti-apoptotic members such as Bcl-2, Bcl-XL
and Bcl-W possess all four BH domains. Other anti-apoptotic
members such as Mcl-1, BHRF-1, and KSHV-Bcl-2 possess
homology only in BH1, BH2 and BH3 domains. The pro-
apoptotic proteins of Bax subclass possess sequence homology
in BH1, BH2 and BH3 domains, while the members of the
BH3 subclass such as Bid have strong homology only in
BH3 region. Firstly discovered member of this family, Bcl-2,
is folded into eight a-helices, possess all four homology do-
mains i.e., BH4 (10–29 amino acids), BH3 (90–107 amino
acids), BH1 (133–152 amino acids), BH2 (184–199 amino
acids) in addition to one X domain (192–203 amino acids)
and one regulatory/ﬂexible loop domain (30–90 amino acids).
Its BH1 and BH2 domains along with BH3 domain form a
solvent accessible hydrophobic receptor cleft essential for het-
erodimerization with pro-apoptotic proteins through their a-
helical, amphipathic BH3 domain [1]. Reports have shown that
BH1 and BH2 domains are essential for co-immunoprecipita-
tion of Bcl-2 with Bax and for prolongation of cell survival in
the setting of induced apoptosis on IL-3 deprivation and gamma
irradiation. Substitution of G145 (in BH1 domain) with A/
E and W188 (in BH2 domain) with A abrogates Bcl-2 hetero-
dimerization potential and its death repressor activity [2,3].
Although the sequence conservation of BH1 and BH2 domains
is known within the Bcl-2 family, their structural conservation
with respect to amino acid residues forming an active site has
never been elucidated. Functional active site of a protein is a
region that performs any of the diverse set of activities includ-
ing acting as an enzyme active site or being a binding region
for a small molecule or a macromolecule [4]. Detailed knowl-
edge of an active site may provide a new insight into the molec-
ular mechanism by which Bcl-2 family members balance
cellular proliferation and death. To analyze the role played
by predicted active site residues in heterodimerization, we
docked Bcl-2 with BH3 domain of pro-apoptotic protein
Bax. The docking results were consistent with the experimen-
tally obtained data for Bcl-XL/Bak and Bcl-XL/Bad complexes
[5,6].
To analyze the structural conservation of residues in BH1
and BH2 domains of Bcl family proteins, we chose Bcl-2 as
a model. The homology models of Bcl-2 and Bax BH3 domaination of European Biochemical Societies.
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Bcl-2 was generated because only the chimeric NMR structure
of Bcl-2 is solved in which the regulatory loop domain was
replaced with that of Bcl-XL [8]. However, to identify con-
served residues in Bcl-2, we needed an intact structure. The
models of Bcl-2 and Bax BH3 domain were checked for their
conformational accuracy in secondary and tertiary structure.
As the sequence of a protein diverges, only those residues
which are required for its biochemical activity, functional
activity, proper folding and transport will be absolutely con-
served so that the structure made of these active site residues
in 3D space should also remain conserved [4]. Therefore, we
identiﬁed the structural homologs of Bcl-2 in PDB database
(Protein Data Bank) [9] and structurally aligned them to ﬁnd
the similar folded residues. This helped us to identify the com-
monality of local structural pattern (active site) in proteins of
Bcl-2 family. The distance between Ca atoms of predicted res-
idues, presumed to be forming an active site in each Bcl-2
structural homolog, was found out to be near the mean value
that suggested their superimposition in both position and ori-
entation. We then docked active site residues in Bcl-2 with
BH3 domain of Bax to analyze their importance in Bcl-2-Bax
heterodimerization. On the basis of these results, we have
hypothesized the structural explanation of reported mutations
in BH1 (G145A, G145E) and BH2 (W188A) domains of
Bcl-2, which functions to abolish its potential as cell survival
regulator.2. Materials and methods
The Bcl-2 and Bax BH3 domain homology models were generated
using SWISS-MODEL, an automated protein homology-modeling ser-
ver available at www.expasy.org. The secondary structure of models
was predicted by NPS@GORI [10] and PredictProtein server [11,12].
The models were analyzed for their correctness in stereochemistry,
non-bonded-atomic interactions, 3D proﬁle and protein volume using
structure analysis and veriﬁcation server (SAVS) [13–18]. We searchedFig. 1. Homology model of Bcl-2 is colored according to RasMol ‘‘Tempe
anisotropic temperature (beta) value stored in the PDB ﬁle. Typically this give
values are colored in warmer (red) colors and lower values in colder (blue) co
RasMol ‘‘Group’’ color scheme, which color codes residues by their position
from blue through green, yellow and orange to red. The N terminus of protePDB database using BLAST 2.2.10 [19] to ﬁnd structural homologs of
Bcl-2 in BH1 and BH2 domains with known tertiary structure. All
homologs were structurally aligned with Bcl-2 in SPDB viewer using
its iterative ﬁt option [20]. The distance between Ca atoms of structur-
ally conserved residues was measured using distance-measuring tool of
SPDB viewer. To show the superimposability of active site, its mean
distance value was calculated. Hex 4.1 was used to dock Bax BH3 do-
main with Bcl-2 homology model. The parameters used were, search
mode-full, post processing-backbone bumps, receptor range-45, li-
gand range-90, electrostatic calculations-enabled and the ﬁnal search
was done at N = 30 [21,22].3. Results
3.1. Structure of Bcl-2 and BH3 domain of pro-apoptotic protein
Bax
All Bcl-2 homology domains (BH1, BH2, BH3, and BH4),
regulatory domain and X domain was modeled by SWISS-
MODEL server except transmembrane domain. It was modeled
from R6 to R207 out of 239 amino acids in Bcl-2 full protein.
In secondary structure conformation, the model shows seven
a helices, a1 (E8–Y23), a2 (V87–R102), a3 (A108–R112), a4
(A121– L132), a5 (T139–N158), a6 (P163–D186) and a7
(D191–L196) and an unstructured loop, which is regulatory/
ﬂexible loop domain. BH3 domain of Bax protein was all a-heli-
cal in secondary structure conformation, encompassing 59–73
amino acid residues (Fig. 1).
3.2. Identiﬁcation of Bcl-2 Structural homologs in BH1 and BH2
domains
The Bcl-2 protein sequence was input as a query in BLAST,
calculation matrix used, BLOSUM62 [24] and E value selected,
100. The proteins with greater than or equal to 40% structural
identity in BH1 and BH2 domains were: 1MAZ (homology
57%) [8], 1BXL (homology 54%) [5], 1PQ0 (homology 57%)
[6], 1PQ1 (homology 57%) [6], 1WSX (homology 52%) [25],
1AF3 (homology 57%) [26], 1G5M (homology 70%) [27],
1GJH (homology 71%) [27], 1LXL (homology 57%) [8],rature’’ color scheme, which color codes each atom according to the
s a measure of the mobility/uncertainty of a given atoms position. High
lors. Homology model of BH3 domain of Bax is colored according to
in a macromolecular chain. Each chain is drawn as a smooth spectrum
ins is colored blue and the C terminus of proteins is drawn in red [23].
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1MK3 (homology 48%) [30], 1F16 (homology 56%) [31],
1Q59A (homology 43%) [32], 1K3K (homology 44%) [33]
and 1TY4 (homology 40%) [34]. Except three proteins, 1K3K,
1Q59 and 1TY4, all proteins were either pro-apoptotic or anti-
apoptotic members of Bcl-2 family. The proteins 1K3K and
1Q59were fromKaposis sarcomavirus 2andEpstein-Barr virus
2, respectively. The 1TY4 protein is a Bcl-2 homolog, CED-9,
present in C. elegans in complex with EGL-1 and CED-4.3.3. Prediction of structurally conserved/active site residues
All Bcl-2 homologs were aligned structurally in SPDB viewer
(Fig. 2). On alignment three residues viz. G145, R146 and
W188 of Bcl-2 were found to be forming a similar fold in each
protein. This prompted us to measure the distance betweenFig. 2. Structural alignment of Bcl-2 homologs showing conservation of gly
Bcl-2 family proteins. PDB ID of homologous proteins is followed by starting
the sequence of Bcl-2 homology model, i.e., G145, R146 and W188.
Table 1
Distance in angstrom (A˚) between residue pair forming an active site in Bcl
Name PDB ID (organism) Structu
residues
Homology model BCL-2 (Human) G145
Bcl-XL 1MAZ (E. coli) G138
Bcl-XL/Bak complex 1BXL (E. coli) G138
Bcl-XL 1PQ0 (Mouse) G138
Bcl-XL/Bim complex 1PQ1 (Mouse) G138
Mcl-1 1WSX (Mouse) G243
Bcl-XL 1AF3 (Rat) G138
Bcl-2 Isoform 1 1G5M (Human) G145
Bcl-2 Isoform 2 1GJH (Human) G145
Bcl-XL 1LXL (Human) G138
Bcl-XL 1R2D (Human) G138
Bcl-XL/Bad complex 1G5J (Human) G142
Bcl-W 1MK3 (Human) G93
Bax-alpha 1F16 (Human) G108
BHRF-1 protein 1Q59A (EB2 virus) G99
Bcl-2 homolog 1K3K (Kaposis sarcoma virus 2) G85
CED-9/EGL-1 complex 1TY4 (C. elegans) G169these three residues in all the proteins. We observed that the
distance between them is almost equal and, the mean distance
was also found to be nearly same (Table 1).
This shows that these residues are superimposable in position
and orientation in 3D space in each structural homolog. It im-
plies that these residues are perhaps involved in the formation
of an active site in Bcl-2 structural homologs and any mutation
within predicted active site is most likely to abrogate the hetero-
dimerization of pro- and anti-apoptotic members of Bcl-2 fam-
ily. This has been demonstrated experimentally for the predicted
residues G145 (in BH1 domain) and W188 (in BH2 domain) in
Bcl-2; their substitution with A disrupts the pore forming ability
of the Bcl-2 protein [35] and completely abrogates its hetero-
dimerization and consequently death repressor activity in IL-3
deprivation, gamma irradiation and glucocorticoid-induced
apoptosis [3,36,37]. Similarly, the substitution of G138A,cine and arginine in BH1 domain and tryptophan in BH2 domain of
amino acid number for each sequence. Residue numbers are shown for
-2 and its family members
rally conserved Distance between active
site forming residues (A˚)
Mean
distance
(A˚)
G–R R–W W–G
R146 W188 3.83 11.92 12.90 9.55
R139 W181 3.82 11.65 12.82 9.43
R139 W181 3.82 12.93 13.53 10.09
R139 W181 3.80 11.62 12.61 9.34
R139 W181 3.79 12.23 13.21 9.74
R244 W286 3.79 12.28 13.21 9.76
R139 W181 3.86 11.82 12.92 9.53
R146 W188 3.79 11.57 12.93 9.43
R146 W188 3.79 11.45 12.64 9.29
R139 W181 3.83 11.42 12.71 9.32
R139 W181 3.82 11.57 12.67 9.35
R143 W185 3.80 12.63 13.15 9.86
R94 W136 3.80 12.41 13.89 10.03
R109 W151 3.82 12.97 14.90 10.56
R100 W143 3.80 10.05 11.35 8.4
R86 W127 3.80 13.01 13.57 10.12
R170 W212 3.80 14.70 16.63 11.71
Fig. 3. (A) Bcl-2 (blue) active site residues interacting with Bax (green). The interacting residues are numbered and shown in spaceﬁlled display in
Rasmol, rest of the residues are shown in ribbon display. (B) R146 forms a double intermolecular hydrogen bond with D68 on one side and a single
intermolecular hydrogen bond with D71 on the other side, which is the main docking site of BH3 domain of pro-apoptotic proteins. This interaction
is shown to stabilize the dimeric complex formation. The residue K64 interacts hydrophobically with W188 in the hydrophobic receptor cleft,
whereas it intramolecularly binds with D68.
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of BH3 receptor cleft of Bcl-XL to pro-apoptotic proteins [5].
3.4. Interaction of active site residues in Bcl-2 with BH3 domain
of Bax
The Bcl-2 protein was docked to BH3 domain of Bax protein
to understand the role of active site residues in Bcl-2 and Bax
heterodimerization. The best docking solution was present
among the ﬁrst energy minimized cluster in Hex-docked com-
plexes (Fig. 3A). The Ca RMS deviation of the best-docked
structure was 1.00 with zero backbone bumps. The active site
residue, R146 of Bcl-2, forms a hydrophilic hydrogen bond
with D68 and D71 of Bax peptide (Fig. 3B). The importance
of hydrogen bonding interaction in between R and D can be
understood from the solved complex of Bcl-XL and Bak pep-
tide (1BXL), where interaction between D83 of Bak and
R139 of Bcl-XL stabilizes the complex formation. D83, which
is completely conserved within Bcl-2 family, when substituted
with A in Bak peptide markedly reduces the binding of peptide
to Bcl-XL. Moreover, conserved R139 mutation to E in Bcl-XL
inhibits its anti-apoptotic activity and binding to Bak protein
[5]. Similarly, the same interaction was observed in three-
dimensional NMR structure of anti-apoptotic protein Bcl-XL
complexed to a 25-residue peptide (1G5J) from the death pro-
moting BH3 region of Bad. In this complex R139 of Bcl-XL
interacts with D156 of Bad peptide [6]. In vivo, Bax mutant
D68A is shown to retain the ability to homodimerize but failed
to interact with Bcl-2, as determined by yeast two-hybrid as-
says and co-immunoprecipitation analysis using transfected
293 mammalian cells. The co-expression of wild type Bcl-2
with Bax mutant, D68A, rescues cells from apoptosis indicat-
ing the importance of D68 in heterodimerization interaction
and induction of apoptosis by inhibiting Bcl-2 cell survival
potential [38].
The other active site residue, W188, was within the docking
distance with K64 of Bax peptide, whereas G145 provides the
space, due to its small size, required for accommodating D68
within the groove formed by G145 and R146. Therefore, it
may be contemplated that any other amino acid in place ofG would sterically inhibit the entry of D68 required to stably
heterodimerize Bax protein with Bcl-2 (Fig. 3A). These interac-
tions were never shown earlier, which account for the abroga-
tion of Bcl-2 activity in which the clones expressing the Bcl-2
mutants G145A/E and W188A in FL5.12 and 2B4 cell lines
were not able to heterodimerize with pro-apoptotic proteins
and subsequently unable to inhibit programmed cell death
[3]. Since substitution of G145A/E and W188A abrogates het-
erodimerization, therefore, we also measured distance between
Ca atoms of G145 and W188. On substitution G145A or
W188A or both, the distance between G145 and W188 remains
the same, however A in place of G and W involves itself in the
formation of an intramolecular hydrogen bond with A149
(with nitrogen) and L185 (with oxygen) in Bcl-2, respectively
(data not shown). The formation of hydrogen bond subse-
quently disturbs the accessible surface of active site in which
A replaces the smaller G and probably suppresses the cleft
accessibility, whereas the side chain of W that may be func-
tionally interacting with, e.g., D64 of pro-apoptotic protein
Bax, is no longer available. The presence of bulky group of
E in G145E substitution perhaps suppresses the stabilization
of heterodimeric complex between anti- and pro-apoptotic
proteins mediated through the predicted active site.
Similar types of interactions were observed in other experi-
mentally solved complexes such as 1BXL, 1PQ1 and 1G5J.
Although there is a diﬀerence in binding aﬃnity of Bcl-2 family
proteins towards pro-apoptotic Bax, Bad, Bim and Bak pep-
tides due to diﬀerence in residues lining the hydrophobic recep-
tor cleft [5,6,27,39], the position of predicted active site
residues remains conserved sequentially as well as structurally
in each of Bcl-2 structural homologs.4. Conclusion and discussion
We have reported here the interaction of only three residues
with Bax protein, however there may be other residual interac-
tions, to verify the presence of an active site in Bcl-2 and its
family members. These three residues may be providing the
G.U. Gurudutta et al. / FEBS Letters 579 (2005) 3503–3507 3507basic structural skeleton onto which pro-apoptotic proteins
sit, whereas the interactions in between other residues decide
the speciﬁcity and eﬃcacy of Bcl-2 family members for
heterodimerization. For example, the three-dimensional struc-
ture of 1Q59 does not contain prominent hydrophobic groove
that mediates binding to pro-apoptotic family members. How-
ever, it does binds to Bax, Bak and to Bad with low aﬃnity.
This binding may be attributed to the predicted active site res-
idues which are structurally conserved in 1Q59 protein also
[32].
This knowledge of structural conservation of residues in
BH1 and BH2 domains of Bcl-2 family members may be
potentially exploited in better understanding of hitherto unre-
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